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Somatostatin is a neuroendocrine peptide with a
wide range of antiproliferative1-4 and antisecretory5
properties. Somatostatin is known to inhibit inflam-
matory cell adhesion,6 and its analogs have been
used experimentally in vivo to inhibit restenosis after
balloon angioplasty,7 vein graft hyperplasia,8 and
transplant arteriosclerosis.9 Somatostatin analogs
have also been used clinically to inhibit restenosis
after coronary angioplasty.10
The development of gene transfer to endothelial
cells (ECs) represents an attractive strategy to pro-
duce recombinant proteins of interest such as
somatostatin in localized areas of the vasculature or
in the blood vessel wall. Gene transfer of somato-
statin to ECs has potential use in a variety of set-
tings, such as reseeding of somatostatin-producing
ECs onto vessels of donor organs to prevent trans-
plant arteriosclerosis or onto sites of arterial injury
to inhibit neointimal hyperplasia and subsequent
restenosis. The ability of genetically altered ECs to
incorporate into normal capillary walls after intraar-
terial injection11 and to localize to sites of angiogen-
esis within the body12 suggests that somatostatin-
producing ECs could be targeted to specific vascular
beds. The delivery of somatostatin using such a gene
transfer strategy could allow long-term localized
production for antiproliferative, antiinflammatory,
or antisecretory purposes. 
The successful production of biologically active
somatostatin by retroviral gene transfer to ECs is
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complicated. Somatostatin is initially produced as a
preprohormone that is sequentially cleaved by
endopeptidases to yield functional somatostatin.
Prosomatostatin undergoes different proteolytic
cleavages to yield different biologically active forms
of somatostatin in various tissues.13 Because endo-
thelium does not normally produce somatostatin
and the expression of prohormone-processing en-
zymes has been shown to be highly tissue specific,14
the post-translational ability of ECs to appropriately
process somatostatin is unknown. Thus biologic
function of somatostatin-transfected ECs may be
limited by improper or incomplete post-translation-
al processing, despite successful gene transfer and
expression. 
A second potential limiting factor of somato-
statin gene therapy using ECs is the possibility of
autocrine or paracrine inhibition of EC proliferation
by the somatostatin itself. It is possible that genetic
modification of endothelium to produce somato-
statin results in failure of the cells to proliferate and
populate an intended in vivo target site. The effects
of somatostatin on EC proliferation are not known. 
The principal purpose of this study was to evalu-
ate whether retroviral gene transfer of somatostatin
to ECs would result in somatostatin gene expression
and appropriate post-translational processing and to
determine the effects of this gene product on EC
growth. Additional studies were performed to com-
pare somatostatin production by different EC types
and to determine possible mechanisms responsible
for differences in somatostatin expression by differ-
ent cell types.
METHODS
EC derivation and culture. Three EC sources
were used in these experiments. The canine venous
ECs (CVECs) were the first type studied. CVECs
were obtained from the external jugular veins of
adult mongrel dogs using a modification of a previ-
ously described technique.15 Briefly, a 10 to 15 cm
segment of external jugular vein was removed from
the neck of 20 to 25 kg mongrel dogs. All animal
experiments were conducted in accordance with the
“Guide for the Care and Use of Laboratory Ani-
mals” (National Institutes of Health publication no.
86-23, revised 1985). The excised vein was everted
and secured over a sterile steel rod. After cold saline
rinses to remove adherent red blood cells, the vein
was incubated in the enzyme Dispase (15 U/ml;
Boehringer-Mannheim Biochemicals, Indianapolis,
Ind.) at 37°C for 150 seconds. The rod with the
attached vein was then spun at varying speeds (60 to
500 rpm) in cold Medium-199 (M-199) (GIBCO,
Grand Island, N.Y.) for 60 seconds to detach EC
clusters. The Dispase incubation and spin were
repeated twice. The M-199 containing the ECs from
the three spins was centrifuged at 1,500 g for 5 min-
utes, and the three EC pellets were resuspended in 5
ml of growth media (M-199 with 5% bovine calf
serum [Hyclone, Logan, Utah], 10 m g/ml EC
growth supplement [Collaborate Biochemical,
Bedford, Mass.], 15 U/ml heparin, 100 units/ml of
penicillin and streptomycin, and 0.68 mM L-gluta-
mine) and maintained on gelatin-coated plates in a
5% CO2 humidified 37°C incubator. Cultures were
fed every 2 to 3 days and split when confluent.
CVEC cell type was confirmed by cell morphology,
lack of staining with an antibody to a -actin, devel-
opment of a confluent monolayer, and uptake of flu-
orescent acetylated low density lipoprotein ligand. 
Rat microvascular ECs (RMVECs), the second
cell type studied, were derived as described previous-
ly11 from epididymal fat pads of male Fischer F344
rats. After digestion with Type Ia collagenase, the
RMVECs were serially filtered across 150 to 212 m m
glass beads, and the fragments were eluted by enzy-
matic dissociation with 0.05% trypsin/0.5 mmol/L
sodium-EDTA. The RMVECs were pelleted and plat-
ed onto gelatin-coated flasks containing Dulbecco’s
modified Eagle’s medium-Ham’s F-12 medium, 5%
fetal bovine serum, 10 m g/ml EC growth supple-
ment, 15 U/ml heparin, 100 units/ml of penicillin
and streptomycin, and 0.68 mM L-glutamine. EC
type was confirmed by monolayer cobblestone
growth and uptake of fluorescent acetylated low den-
sity lipoprotein. RMVECs were used in the 30th to
35th passage, previously documented to survive long
term in vivo after retroviral transduction and cell
transplantation.11
Rat aortic ECs (RAECs), the third cell type
studied, were derived using an outgrowth tech-
nique.16 Thoracic aortic rings (5 mm long) of male
Fischer F344 rats were placed in tissue culture flasks
precoated with Matrigel and containing RAEC
media (M-199, 20% fetal bovine serum, 20 m g/ml
EC growth supplement, 15 U/ml heparin, 100
units/ml of penicillin and streptomycin, and 0.68
mM L-glutamine) and removed after 72 hours.
Outgrowth of smooth muscle cells from rat arterial
explants takes 2 to 3 weeks, and thus removal of the
aortic rings by 72 hours is well before smooth mus-
cle cell outgrowth. The RAECs adherent to the
flask were grown to confluence, passaged with 0.5%
trypsin/EDTA, and plated onto gelatin-coated
flasks in RAEC media. RAEC cell type was con-
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firmed with negative immunofluorescent staining
with an a -actin antibody (HHF-35; Sigma
Chemical, St. Louis, Mo.) and positive staining
with antibodies to factor VIII.
Retroviral construction and transfection. To
allow transfection of a variety of different species of
ECs, an amphotropic somatostatin retrovirus was
constructed. Ecotropic retroviral supernatant con-
taining the cDNA for human somatostatin (HSS)
was used to transfect the pLJ retroviral producer cell
line. Producer clones were isolated by plating in
medium containing 1 m g/ml G418 and expansion
of individual colonies. Titers were determined indi-
vidually for clones, and a producer line was isolated
that was capable of producing 50,000 G418-resis-
tant colonies/ml (plaque-forming units/ml) of
supernatant. A structurally identical retroviral pro-
ducer line containing the b -galactosidase marker
gene (pLJ-BAG) in place of somatostatin was used
for control transfections. The pLJ retroviral back-
bone contains the Tn5 neomycin phosphotrans-
ferase gene to allow selection of transfected cells
using the neomycin class of antibiotics (Genecin
G418). This allows the isolation of a pure popula-
tion of cells that have incorporated and express the
retrovirus. In both our constructs, the cDNA of
interest (somatostatin or b -galactosidase) was driven
by the viral long terminal repeat promoter and the
Tn5 selection gene was driven by a Simian virus 40
promoter (Fig. 1).
All types of ECs to be transfected (second or third
passage for CVECs and RAECs and 30th to 35th pas-
sage for RMVECs) were split 1:5 the day before trans-
fection to maximize the number of replicating cells
capable of undergoing retroviral gene transfer. Viral
supernatant was generated by changing the medium
(Dulbecco’s modified Eagle’s medium, 10% bovine
calf serum) over recently confluent producer cells and
harvesting the medium 12 hours later. This super-
natant was filtered through a 0.45 m m filter to remove
any detached live producer cells. It was used immedi-
ately or frozen at - 70°C for later use. The cationic
agent Polybrene (8 m g/ml) was added to the viral
supernatant immediately before use. ECs were
exposed to the viral supernatant for 8 hours and then
fed again with appropriate fresh media. After a 48-
hour period to allow reverse transcription of the viral
RNA genome, incorporation of the DNA provirus
into a host chromosome, and expression of the trans-
genes, the cells were split 1:8 into appropriate com-
plete medium supplemented with G418 at 1 mg/ml.
Nontransduced ECs from the same passage were
simultaneously split into G418-containing medium to
serve as markers for complete death of cells not incor-
porating retrovirus. All cells were maintained in
G418-containing medium for approximately 14 days,
or 3 days after all the nontransduced cells had died.
Control ECs for all experiments were transduced with
the BAG marker retrovirus using identical procedures
as described above except with the BAG retroviral
supernatant used for transduction.
Analysis of gene expression. Somatostatin pro-
duction was assayed by measuring its level in medi-
um from confluent monolayers of BAG- and HSS-
transduced ECs that had been collected after
24-hour incubations and stored at - 70°C for subse-
quent radioimmunoassay. The radioimmunoassay
used synthetic somatostatin-14 as a standard and an
antibody (Antibody 1001)17 that binds to the car-
boxyl terminus of somatostatin and therefore
allowed recognition of both somatostatin-14 and
somatostatin-28, as well as larger forms of somato-
statin. All comparisons with HSS-transfected cells
included BAG-transduced cells as the controls to
ensure that observed differences reflected actual
gene transfer and expression of somatostatin and not
perturbations secondary to the retroviral transduc-
tion and selection process alone.
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Fig. 1. Retroviral vectors used to transfect ECs. BAG vector (top) with bacterial b -galactosidase
gene driven by retroviral long terminal repeat (LTR) promoter. Neomycin phosphotransferase
gene (neomycin) is driven by the Simian virus 40 (SV40) promoter. Human somatostatin vector
with the human somatostatin cDNA (somatostatin) in place of b -galactosidase gene.
The type of somatostatin produced by trans-
duced ECs was determined using column chro-
matography to separate somatostatin subtypes in the
medium from transduced ECs and allow comparison
with somatostatin peptide standards. Samples were
diluted with buffer A (0.1% trifluoroacetic acid) and
applied to an HR 5/5 pepRPC fast protein liquid
chromatography (Pharmacia, Piscataway, N.J.) col-
umn previously equilibrated with buffer A. A gradi-
ent with buffer B (buffer A with 50% acetonitrile)
was run for 60 minutes at 0.5 ml/min with a linear
gradient from 0% B to 40% B for 25 minutes, fol-
lowed by an increase to 41.3% B for an additional 23
minutes and then to 100% B for the final 12 min-
utes. Fractions (0.5 ml) were collected and assayed
for somatostatin-like immunoreactivity with Anti-
body 1001. Columns were initially calibrated with
human synthetic somatostatin-14 and somatostatin-
28 (Peninsula, Belmont, Calif.), and the elution pro-
files of EC medium were compared with these stan-
dards (Fig. 2). Somatostatin-14 and somatostatin-
28 were eluted at 40.2% and 40.3% B, respectively.
We initially intended to use our EC supernatants in
a bioassay for somatostatin activity. The lower limit
of sensitivity of this assay, used to measure inhibition
of gastric release from enterocytes, is approximately
10 nmol/L, which is 20-fold higher than the level of
somatostatin present in the supernatants.
Retroviral transfer of the b -galactosidase marker
gene was assayed using a histochemical marker of
gene expression in confluent EC monolayers. ECs
grown to confluence in T-25 culture flasks were
rinsed twice with phosphate-buffered saline and then
incubated with the chromogenic substrate 5-bromo-
4-chloro-3-indoyl b -D-galactosidase overnight at
37°C with gentle agitation.11
Growth studies. The proliferation of BAG-
and HSS-transduced CVECs was assessed in cells
one to three passages after transduction and selec-
tion. ECs were plated at a concentration of 5,000
cells/cm2 onto 12-well plates, as determined by
quantification of aliquots of cells with a Coulter
counter (Coulter Electronics, Hialeah, Fla.). Initial
counts (day 0) were obtained 24 hours after plat-
ing. The medium was changed every 48 hours, and
cell counts were determined after 96 hours. We
chose to evaluate overall cell growth by determin-
ing the change in EC number to ensure detection
of any inhibition of cellular mitosis or other
processes that might escape detection by assay of
DNA synthesis alone. ECs were detached for
counting by exposure to trypsin. Increases in cell
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Fig. 2. Analysis of somatostatin peptide produced by
transfected CVEC. A, Chromatographic separation of
somatostatin-14 and somatostatin-28 peptide standards
followed by somatostatin immunoreactivity assay. B,
Analysis of HSS EC medium under same conditions.
Fig. 3. Somatostatin production by BAG- and HSS-
transfected CVECs. Transfected CVECs were grown to
confluence, and the medium was replaced and collected
after 24 hours for somatostatin immunoreactivity determi-
nation (n = 3, *p < 0.05 vs BAG group).
number were calculated by subtracting the day 0
cell counts from the final counts.
Statistical analysis. An unpaired t test was used
for comparisons between two groups. Analysis of
variance with correction for multiple comparisons
was used for comparisons among several groups. All
data are presented as the mean ± standard error.
Differences were considered significant at p < 0.05.
RESULTS
Transduction and selection of canine ECs with
BAG and HSS retroviral vectors resulted in the
growth of numerous G418-resistant cells. HSS-
transfected ECs generated immunoreactive somato-
statin at 24 hours in the range of 450 ± 32 pmol/L
(Fig. 3). BAG-transfected canine ECs at the same
time period demonstrated significantly less immuno-
reactivity (49 ± 10 pmol/L). This residual immuno-
reactivity was the same as that in medium from non-
transduced ECs and in fresh (nonconditioned)
medium (data not shown) and thus reflected the
somatostatin present in the bovine serum used in all
experiments. Attempts to use serum-free medium
for 24 to 48 hours resulted in significant detachment
and loss of ECs; consequently, the somatostatin
determinations were made with medium-containing
serum and, therefore, some background somato-
statin immunoreactivity. 
HSS-transduced cells appear to properly process
the somatostatin peptide product. Column chroma-
tography combined with the somatostatin radioim-
munoassay (Fig. 2A) allowed precise resolution of
somatostatin-14 and somatostatin-28. Analysis of
the medium from HSS-transfected canine ECs
under the same assay conditions revealed that ECs
processed the preprosomatostatin into somatostatin-
14 (Fig. 2B). Additional somatostatin immunoreac-
tivity that eluted early from the column most likely
represented somatostatin-14 that became degraded
during the 24-hour medium incubation as reported
previously.4
Somatostatin production by CVECs did not
appear to affect cellular proliferation and suggested
an absence of paracrine or autocrine growth inhibi-
tion. An analysis of CVEC numbers after 96 hours
of growth demonstrated no difference in the rate of
proliferation between HSS-transfected canine ECs
and BAG-transfected controls (Fig. 4).
HSS and BAG retroviral transduction of RAECs
and RMVECs did not result in significant somato-
statin production. Despite the isolation and growth
of G418-resistant colonies of RAECs and RMVECs,
neither rodent EC type generated significant so-
matostatin immunoreactivity in the medium com-
pared with BAG-transduced controls (Fig. 5). The
HSS-transfected RAECs and RMVECs had under-
gone retroviral transduction and expressed the Tn5
neomycin phosphotransferase gene present in the
retrovirus, as demonstrated by their ability to grow
continuously in medium-containing concentrations
of G418 lethal to their nontransduced counterparts.
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Fig. 4. Growth of CVECs over 96 hours after transfec-
tion with BAG or HSS retrovirus. After retroviral trans-
fection and selection, cells were plated at a concentration
of 5,000 cells/cm2, and the increase in cell number over
96 hours was determined (n = 4 per group).
Fig. 5. Somatostatin production by various EC types
after BAG and HSS transfection and selection. Transfected
ECs were grown to confluence, and the medium was
changed and collected after 24 hours for somatostatin
immunoreactivity determination (n = 3, *p < 0.05 vs all
other groups).
Histochemical staining for b -galactosidase in all
three types of ECs after BAG transduction revealed
marked differences in transgene expression that par-
alleled the disparities in somatostatin production
(Fig. 5). BAG-transfected CVECs exhibited consis-
tent and uniform b -galactosidase expression
throughout the monolayer (Fig. 6A) consistent with
relatively high levels of somatostatin production in
their HSS-transfected canine counterparts. In con-
trast, both RAECs and RMVECs transfected with
the BAG retrovirus displayed numerous cells in the
monolayer that did not express b -galactosidase
despite selection in G418 medium (Figs. 6B and
6C). This finding correlated with low-level expres-
sion of somatostatin after transfection with the HSS
retrovirus of these two EC types.
DISCUSSION
Important findings of this investigation include
that (1) ECs are capable of processing and secreting
the somatostatin peptide product, (2) CVECs pro-
duce primarily somatostatin-14, supporting the exis-
tence of somatostatin-processing endopeptidases in
ECs, (3) production of biologically relevant concen-
trations of somatostatin-14 does not inhibit EC
growth, (4) there is significant variation among EC
types in their production of somatostatin after retro-
viral transduction and selection, and (5) variations in
somatostatin production by EC type correlate with
variations in expression of b -galactosidase after simi-
lar retroviral transduction.
The efficacy of transgene expression after retro-
viral transduction was evaluated by analysis of the
protein products, namely the somatostatin peptide
(Figs. 2 and 5) and b -galactosidase enzyme activity
(Fig. 6). Although Southern and Northern blot
analyses have been used to determine incorporation
of retroviral DNA and production of retroviral
mRNA,18 neither provides information regarding
actual protein production, something that is partic-
ularly crucial when multiple post-translational pep-
tide-processing steps are required, as in the case of
somatostatin.19
The concentrations of somatostatin produced by
HSS-transduced CVEC in the current study have
been reported to inhibit in vitro proliferation of
prostate cancer cells,3 breast carcinoma,2 T lympho-
cytes,4 and vascular smooth muscle cells.1 Direct
extrapolation of these in vitro findings to an in vivo
effect is not possible. However, the similarity in these
concentrations coupled with the reported in vivo
inhibition of neointimal hyperplasia,7 tumor
growth,20 and transplant arteriosclerosis9 by somato-
statin analogs suggests that somatostatin gene trans-
fer to ECs may prove useful as an in vivo therapy.
The HSS-transduced CVECs produced somato-
statin-14 (Fig. 2), the predominant form of the pep-
tide produced normally in the pancreas, intestines,
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Fig. 6. Microscopic analysis of heterogeneity of b -galactosidase expression in endothelium
after BAG transfection and selection. A, Canine venous endothelium (CVECs). B, Rat aortic
endothelium (RAECs). C, Rat microvascular endothelium (RMVECs). Shown are cells
expressing b -galactosidase (arrow) or not expressing b -galactosidase (arrowhead). Original
magnification, · 100. 
and brain.19 Thus the dibasic endopeptidases re-
sponsible for post-translational processing of so-
matostatin appear to be present in ECs and are
capable of processing the preprosomatostatin gener-
ated by heterologous expression of the human
somatostatin cDNA.
The fact that the growth of HSS-transfected
CVECs was similar to that of BAG-transfected
CVECs in this study (Fig. 4) suggests that somato-
statin does not cause an autocrine or a paracrine
inhibition of EC proliferation. This may be due to a
lack of somatostatin receptors on ECs or a lack of
other cell-type specific mechanisms necessary for
somatostatin inhibition of proliferation. This is the
first report of the lack of an effect of somatostatin on
EC proliferation, and the results support the tenet
that ECs are a reasonable target for somatostatin
gene transfer. 
Gene transfer of somatostatin to other species of
ECs was an additional focus of study. This was con-
sidered important because somatostatin-producing
rat endothelium would be useful in experimental
studies involving cell reseeding after rat endarterec-
tomy21 and EC seeding of rat arterial prosthetic
grafts.22 We purposely did not use human umbilical
vein ECs (HUVECs) in our study for two reasons.
First, they are essentially an embryonic cell type, and
there are significant differences between HUVECs
and adult arterial ECs. Second, HUVECs would
never be used in an animal model (or clinical setting)
for reseeding of an arterial site, and thus somato-
statin production by HUVECs would have limited
significance for both further experimental and clini-
cal studies.
In this study, the failure of EC types other than
CVECs to produce somatostatin after successful
retroviral transduction (Fig. 5) correlated with their
failure in expression of the b -galactosidase gene after
similar transduction and selection (Fig. 6). This find-
ing has been described previously as “promoter
silencing” with dissimilar expression of two trans-
genes contained in a single retroviral construct.
When selection pressure is applied (e.g., survival in
G418-containing medium), which enforces expres-
sion of the G418-resistance gene, the expression of
the other transgene ( b -galactosidase or somato-
statin) is variable and often absent. This mechanism
could be partially responsible for the lack of somato-
statin production by the rodent ECs. Expression of
the Tn5 neomycin phosphotransferase was ensured
by the selection pressure of growth in G418 medi-
um. However, expression of the somatostatin or b -
galactosidase cDNA was under no similar biologic
selection pressure and occurs minimally in terms of
somatostatin levels (Fig. 5) and in an apparently ran-
dom fashion when b -galactosidase expression is
examined (Fig. 6).
The confirmation of promoter silencing as the
mechanism responsible is quite difficult because the
process occurs on a cell-to-cell basis. Standard analy-
sis of mRNA expression, such as Northern blotting,
will not confirm promoter silencing because it ana-
lyzes pooled mRNA from the entire population of
cells. The only way to “prove” that promoter silenc-
ing is occurring is to isolate individual clones of
transduced cells and then demonstrate differences in
transcription between clones. Our analysis of cell-to-
cell protein expression (Fig. 6), although not prov-
ing that the differences occur at the level of tran-
scription, certainly demonstrates marked variation in
b -galactosidase expression between cells that
expressed the Tn5 neomycin resistance gene (as
demonstrated by growth in G418 medium). It is
also possible that this variation is due to differences
in posttranscriptional processing between cells,
instead of promoter silencing.
The biologic basis for this lack of transgene
expression has been reported to be the cis-acting
inhibition of transgene expression by the Tn5
neomycin phosphotransferase gene.23 This decreases
transcription of the other gene in the retroviral con-
struct regardless of the nature of the other gene, the
orientation of the Tn5 gene, or the promoter se-
quence driving the transgene. The promoter se-
quence, or DNA that causes transcription of the
adjacent gene, is often a viral sequence, and in our
vectors, it is the endogenous promoter in the retro-
virus. Such a mechanism of nonspecific inhibition of
transgene expression by the resistance marker gene is
consistent with our data demonstrating a similar
decrease in both somatostatin and b -galactosidase
expression despite successful retroviral transfection
and growth of transfected rodent ECs under selec-
tion conditions.
Retroviruses infect only cells that are actively
replicating at the time of viral exposure and thus
have very poor levels of gene transfer to in vivo vas-
cular tissues, where there is virtually no cell replica-
tion in unperturbed vessels. Retroviruses are there-
fore not the vectors of choice for direct gene trans-
fer, although they are very effective in cultured cells.
We thus focused our study on gene transfer to cul-
tured ECs, which have been successfully reseeded
onto both grafts and native arteries21,23 as a means
of achieving gene transfer to a vessel. 
This study is the first report of somatostatin pro-
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duction by endothelium. Our finding that the pro-
moter silencing of both the somatostatin and b -
galactosidase genes was species specific suggests that
retroviral gene transfer strategies involving ECs must
test for promoter silencing by evaluating a reporter
gene such as b -galactosidase. Such evaluation differ-
entiates problems with transgene peptide processing
from nonuniform expression in cells that fail to pro-
duce desired levels of the transgene of interest. The
finding that CVECs produce and appropriately
process physiologically relevant concentrations of
somatostatin after retroviral gene transfer suggests
that somatostatin gene transfer to ECs could be
therapeutically useful.
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